Opus Genetics

RAMAT GAN, Israel, Aug. 3, 2026 Can-Fite BioPharma Ltd. has launched its first clinical development program evaluating Piclidenoson for...

RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...

RESEARCH TRIANGLE PARK, N.C., July 9, 2026 Opus Genetics announced an important clinical development update for its Phase 1/2...

RESEARCH TRIANGLE PARK, N.C., July 6, 2026 Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has...

RESEARCH TRIANGLE PARK, N.C., May 7, 2026 Opus Genetics announced new clinical and preclinical data presentations at the 2026...

RESEARCH TRIANGLE PARK, N.C. – May 4, 2026 Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5...

Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited...